Results Of The Votes Of The Combined Shareholders' General M...| MENAFN.COM

Friday, 03 February 2023 03:37 GMT

Results Of The Votes Of The Combined Shareholders' General Meeting Of January 25, 2023


(MENAFN- GlobeNewsWire - Nasdaq) English French

Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders' General Meeting.

The Combined Shareholders' Meeting was held on January 25, 2023 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France), under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva.

Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mr. Pierre Broqua and Mr. Jean Volatier, as tellers, as well as Mr. Eric Duranson, as secretary of the general meeting.

All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the eleventh, as recommended by the Board of Directors.

Information on the results of the votes is detailed below:

  • Total number of shares composing the share capital: : 42 134 169
  • Total number of shares with voting rights: 42 027 480



Ordinary part Extraordinary part
Shareholders Shares Votes Shareholders Shares Votes
Shareholders present 0 0 0 0 0 0
Proxy to third parties 0 0 0 0 0 0
Proxy to the Chairman 119 2 060 712 2 188 682 119 2 060 712 2 188 682
Mail votes 84 24 451 455 36 586 555 84 24 451 455 36 586 555
TOTAL 203 26 512 167 38 775 237 203 26 512 167 38 775 237
Quorum 63,082 % 63,082 %

VOTE RESULTS
Ordinary Resolutions
Resolution Result For Against Abstention Total number of votes cast Number of represented shares Proportion of represented share capital Quorum
Votes % Votes % Votes %
1 Adopted 38 758 418 99.96 % 15 859 0.04 % 960 - 38 774 277 26 512 167 62.923 % 63.082 %
16 Adopted 38 755 524 99.95 % 18 504 0.05 % 1 209 - 38 774 028 26 512 167 62.923 % 63.082 %


VOTE RESULTS
Extraordinary Resolutions
Resolution Result For Against Abstention Total number of votes cast Number of represented shares Proportion of represented share capital Quorum
Votes % Votes % Votes %
2 Adopted 35 614 593 91.85 % 3 160 114 8.15 % 530 - 38 774 707 26 512 167 62.923 % 63.082 %
3 Adopted 35 607 497 91.83 % 3 167 160 8.17 % 580 - 38 774 657 26 512 167 62.923 % 63.082 %
4 Adopted 35 605 052 91.83 % 3 169 505 8.17 % 680 - 38 774 557 26 512 167 62.923 % 63.082 %
5 Adopted 35 605 302 91.83 % 3 169 355 8.17 % 580 - 38 774 657 26 512 167 62.923 % 63.082 %
6 Adopted 35 605 466 91.83 % 3 169 090 8.17 % 681 - 38 774 556 26 512 167 62.923 % 63.082 %
7 Adopted 35 606 951 91.83 % 3 167 646 8.17 % 640 - 38 774 597 26 512 167 62.923 % 63.082 %
8 Adopted 35 607 577 91.83 % 3 167 181 8.17 % 479 - 38 774 758 26 512 167 62.923 % 63.082 %
9 Adopted 35 608 177 91.83 % 3 166 430 8.17 % 630 - 38 774 607 26 512 167 62.923 % 63.082 %
10 Adopted 35 608 127 91.83 % 3 166 280 8.17 % 830 - 38 774 407 26 512 167 62.923 % 63.082 %
11 Rejected 10 448 947 26.95 % 28 325 160 73.05 % 1 130 - 38 774 107 26 512 167 62.923 % 63.082 %
12 Adopted 38 751 168 99.94 % 23 539 0.06 % 530 - 38 774 707 26 512 167 62.923 % 63.082 %
13 Adopted 35 608 520 91.84 % 3 164 553 8.16 % 2 164 - 38 773 073 26 512 167 62.923 % 63.082 %
14 Adopted 35 606 496 91.83 % 3 167 922 8.17 % 819 - 38 774 418 26 512 167 62.923 % 63.082 %
15 Adopted 35 602 218 91.82 % 3 171 900 8.18 % 1 119 - 38 774 118 26 512 167 62.923 % 63.082 %

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva reported positive results from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and received Breakthrough Therapy and Fast Track status from the U.S. Food and Drug Administration (“FDA”) for lanifibranor in the treatment of NASH.

Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). .

Contacts

Inventiva
Pascaline Clerc
VP of Global External Affairs

+1 240 620 9175
Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux /
Matthieu Benoist
Media relations

+33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank
Investor relations

+1 415 513-1284

Important Notice

This press release contains“forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva's pipeline and preclinical and clinical development plans, future activities, expectations, plans, growth and prospects of Inventiva and its product candidates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation,“believes”,“anticipates”,“expects”,“intends”,“plans”,“seeks”,“estimates”,“may”,“will”,“would”,“could”,“might”,“should”, and“continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrolment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine, related sanctions and related impacts and potential impacts on the initiation, enrolment and completion of Inventiva's clinical trials on anticipated timelines and macroeconomic conditions, including global inflation and uncertain financial markets or at all. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022, the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 and the financial report for the first half of 2022 filed with the Securities and Exchange Commission on September 22, 2022 for additional information in relation to such factors, risks and uncertainties.

All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above.

Attachment

  • inventiva - pr - results ag 2023 - en - 26 01 2023



Tags shareholders general assembly biotech inventiva $iva #nash Attachments Inventiva - PR - Results AG 2023 - EN - 26 01 2023...

MENAFN26012023004107003653ID1105479238


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.